ReviewJournal of experimental & clinical cancer research : CR2026
cGAS-STING pathway regulated by spatiotemporal heterogeneity of tumor microenvironment and precision therapy strategies in lung cancer.
Review in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The cGAS-STING pathway is a central regulator of innate immunity and exhibits a complex dual function in lung cancer: it can activate anti-tumor immune responses but also promote immune escape and metastasis. This "double-edged sword" effect is highly dependent on the spatiotemporal heterogeneity of the tumor microenvironment (TME), referring to dynamic changes in immune and metabolic features across different regions and disease stages. To optimize existing therapies, overcome resistance, and develop novel treatments to improve patient outcomes, it is crucial to deeply understand the interaction between the TME and the cGAS-STING pathway. This review systematically discusses the pro-tumor and anti-tumor mechanisms of the cGAS-STING pathway in lung cancer; the modulation of cGAS-STING pathway activity by TME spatiotemporal heterogeneity, via the dynamic interplay of distinct cell types and physicochemical gradients; and cGAS-STING-driven precision immunotherapy and artificial intelligence (AI) optimization. Integrating TME spatiotemporal heterogeneity, immunometabolism crosstalk, with cGAS-STING pathway function may provide new insights for improving therapeutic strategies, reversing resistance, and enhancing survival outcomes for lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.